ANGLE and BioView partner to develop a CTC-based HER2 assay

pharmafile | April 19, 2023 | News story | Medical Communications  

ANGLE, a liquid biopsy company, and BioView, a company developing, manufacturing and marketing automated microscopy imaging and analysis solutions, have announced a partnership to develop a liquid biopsy circulating tumour cell (CTC) HER2 assay for breast cancer.


The partnership will leverage ANGLE’s FDA-approved Parsortix PC1 Clinical System to harvest CTCs and BioView’s automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs through analysis of fluorescence intensities.


Compared to standard-of-care, a CTC HER2 assay-based care could be used in longitudinal monitoring of HER2 status throughout disease progression. This would allow medical staff to adjust treatment where necessary to ensure the most appropriate treatment option is being used at every stage.


Development of the assay is expected to take around a year, with the assay development work generating an estimated £1.2m in revenue for ANGLE.


ANGLE founder and CEO, Andrew Newland, commented: “We are delighted to have entered into this partnership with BioView utilising our established bespoke assay development capability. The changing breast cancer treatment landscape has created a major commercial opportunity for a CTC-based HER2 assay allowing repeat testing and longitudinal monitoring of patients to personalise cancer care. We believe this new ‘content’ will drive wide adoption of the Parsortix system in the treatment of breast cancer.”


BioView president and CEO, Dr Alan Schwebel, added: “We are excited for this development partnership opportunity with ANGLE, where we plan to leverage the strengths of both our technologies to develop an impactful liquid biopsy HER2 CTC test. CTCs present a unique opportunity to access protein and/or genomic alterations of HER2 throughout the patient’s cancer treatment to help ensure eligibility for the right therapy to improve patient outcomes.”


James Spargo

Related Content

No items found

Latest content